{
  "id": "5e494b0e6d0a277941000007",
  "type": "list",
  "question": "List 3 PD-L1 inhibitors on the market as of 2018.",
  "ideal_answer": "Atezolizumab (Tecentriq), Avelumab (Bavencio), and Durvalumab (Imfinzi) are PD-L1 inhibitors",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29571563"
  ],
  "snippets": [
    {
      "text": "PD-L1 ICI, such as atezolizumab (TECENTRIQ\u00ae, Genentech), durvalumab (IMFINZI\u00ae, Astra-Zeneca), and avelumab (BAVENCIO\u00ae, EMD Serono",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571563",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)"
}